{"product_id":"global-next-generation-cancer-diagnostic-market-size-study-forecast-by-technology-next-generation-sequencing-qpcr-multiplexing-lab-on-a-chip-loac-reverse-transcriptase-pcr-rt-pcr-protein-microarrays-dna-microarrays-by-application-biom","title":"Global Next Generation Cancer Diagnostic Market Size study \u0026 Forecast, by Technology ( Next-Generation Sequencing, qPCR \u0026 Multiplexing, Lab-on- a- chip (LOAC) \u0026 Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays) by Application (Biom","description":"\u003cp\u003eGlobal Next Generation Cancer Diagnostic Market Size study \u0026amp; Forecast, by Technology ( Next-Generation Sequencing, qPCR \u0026amp; Multiplexing, Lab-on- a- chip (LOAC) \u0026amp; Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays) by Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis), by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), by Function(Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis) and Regional Analysis, 2022-2029\u003cbr\u003e\nGlobal Next Generation Cancer Diagnostic Market is valued at approximately USD 7.98 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 12.38% over the forecast period 2022-2029. Cancer diagnostics is a technique that looks for various proteins, biomarkers, and symptoms to identify the presence of malignant tumours in patients. The method of identifying cancer involves the extensive use of specific technologies and diagnostic tools. The Next Generation Cancer Diagnostic market is expanding because of factors such as the increasing incidence of Cancer, the development of cluster chip technology and potential applications of CTC in cancer management.\u003c\/p\u003e\n\n\u003cp\u003eThe rising prevalence of cancer globally is fostering market growth, according to estimates from the International Agency for Research on Cancer (IARC), The estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040 from 1.9 million new cases in year 2021. Furthermore, rising FDA approval for product and technological development along with rising demand for preventive medicine \u0026amp; companion diagnostics and rising cancer medicine research and development activities is creating lucrative growth in the market. For instance, in August 2022, using a pilot project to enhance the validation and regulatory review process for cancer diagnostics based on next-generation sequencing, the Medical Device Innovation Consortium (MDIC), a public-private partnership with US Food and Drug Administration is working to advance medical device regulatory science, announced on Monday that it has begun the next phase of the Somatic Reference Samples (SRS) Initiative (NGS). However, the requirement of an expensive laboratory set-up for the implementation of novel tests may halt market growth.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Next Generation Cancer Diagnostic Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nJanssen Global Services, LLC\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nKoninklijke Philips N.V.\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nGE Healthcare\u003cbr\u003e\nThermo Fisher Scientific, Inc\u003cbr\u003e\nAgilent Technologies (Dako) Inc\u003cbr\u003e\nIllumina, Inc.\u003cbr\u003e\nOpko Health, Inc\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In February 2022, Becton and Dickinson Corporation (BD) procured Cytogons in order to secure exclusive access to cutting-edge assays licensed from the EuroFlow Consortium and to solidify BD's position as the industry leader in molecular oncology diagnostics.\u003c\/p\u003e\n\n\n\n\u003cp\u003eGlobal Next Generation Cancer Diagnostic Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Technology, Application, Cancer Type, Function, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technologyofferings of key players. The detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Technology:\u003cbr\u003e\nNext-Generation Sequencing\u003cbr\u003e\nqPCR \u0026amp; Multiplexing\u003cbr\u003e\nLab-on- a- chip (LOAC) \u0026amp; Reverse Transcriptase-PCR (RT-PCR)\u003cbr\u003e\nProtein Microarrays\u003cbr\u003e\nDNA Microarrays\u003c\/p\u003e\n\n\u003cp\u003eBy Application:\u003cbr\u003e\nBiomarker Development\u003cbr\u003e\nCTC Analysis\u003cbr\u003e\nProteomic Analysis\u003cbr\u003e\nEpigenetic Analysis\u003cbr\u003e\nGenetic Analysis\u003c\/p\u003e\n\n\u003cp\u003eBy Cancer Type:\u003cbr\u003e\nLung Cancer\u003cbr\u003e\nBreast Cancer\u003cbr\u003e\nColorectal Cancer\u003cbr\u003e\nCervical Cancer\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eBy Function:\u003cbr\u003e\nTherapeutic Monitoring\u003cbr\u003e\nCompanion Diagnostics\u003cbr\u003e\nPrognostics\u003cbr\u003e\nCancer Screening\u003cbr\u003e\nRisk Analysis\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRoLA\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nJanssen Global Services, LLC\u003cbr\u003e\nNovartis AG\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nKoninklijke Philips N.V.\u003cbr\u003e\nAbbott Laboratories\u003cbr\u003e\nGE Healthcare\u003cbr\u003e\nThermo Fisher Scientific, Inc\u003cbr\u003e\nAgilent Technologies (Dako) Inc\u003cbr\u003e\nIllumina, Inc.\u003cbr\u003e\nOpko Health, Inc\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 200 Pages \/ MCW16229808","offer_id":47647004131634,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true},{"title":"May, 2023 \/ 200 Pages \/ MCW16229809","offer_id":47647004164402,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-next-generation-cancer-diagnostic-market-size-study-forecast-by-technology-next-generation-sequencing-qpcr-multiplexing-lab-on-a-chip-loac-reverse-transcriptase-pcr-rt-pcr-protein-microarrays-dna-microarrays-by-application-biom","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}